AD-HOC-NEWS from 05.05.2017

[et_pb_section bb_built=“1″][et_pb_row][et_pb_column type=“4_4″][et_pb_text _builder_version=“3.7″]

HAEMATO AG: Capital increase from authorized capital under exclusion of existing shareholders‘ subscription rights resolved and successfully implemented.

The Management Board of HAEMATO AG, Schönefeld, (ISIN: DE0006190705) decided today with the approval of the Supervisory Board on the basis of the authorized capital of the company to increase the share capital by EUR 1,202,102.00 excluding the subscription rights of existing shareholders. The capital increase has been successfully completed.

The company’s share capital will increase by EUR 1,201,102.00 from EUR 20,778,898.00 to EUR 21,980,000.00 following the entry of the capital increase in the Commercial Register, which is expected in the near future.

The new shares were placed at a price of EUR 6.20 per share. The shares were subscribed by MPH Mittelständische Pharma Holding AG.

The company will receive gross issue proceeds of approximately EUR 7.4 million from the capital increase. The proceeds from the capital increase are intended to further strengthen the equity of HAEMATO AG and create the conditions for the consistent implementation of the growth strategy of the HAEMATO Group. In particular, the development of products with attractive margins is to be further expanded.


Go back

For investors

Do you have any further questions about the group? Our investor relations team is happy to help you..

Contact us